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Strengths and limitations of this study
 ► This study provides the first comprehensive evalua-
tion of the epidemiology of placenta previa compli-
cated by placenta accreta spectrum (PAS).
 ► The search was performed using predetermined 
eligibility criteria in a defined obstetric population.
 ► Thirteen out of 20 studies included in the study 
were retrospective limiting the overall quality of the 
analysis.
 ► Only six studies provided data on the prenatal ul-
trasound diagnosis of PAS in patients with placenta 
previa and nine studies on detailed histopathological 
findings.
 ► High level of inconsistency between estimates in 
prevalence and incidence did not allow for full meta- 
analysis of the clinical outcomes.
AbStrACt
Objective To estimate the prevalence and incidence of 
placenta previa complicated by placenta accreta spectrum 
(PAS) and to examine the different criteria being used for 
the diagnosis.
Design Systematic review and meta- analysis.
Data sources PubMed, Google Scholar,  ClinicalTrials. gov 
and MEDLINE were searched between August 1982 and 
September 2018.
Eligibility criteria Studies reporting on placenta previa 
complicated by PAS diagnosed in a defined obstetric 
population.
Data extraction and synthesis Two independent 
reviewers performed the data extraction using a 
predefined protocol and assessed the risk of bias using 
the Newcastle- Ottawa scale for observational studies, with 
difference agreed by consensus. The primary outcomes 
were overall prevalence of placenta previa, incidence 
of PAS according to the type of placenta previa and the 
reported clinical outcomes, including the number of 
peripartum hysterectomies and direct maternal mortality. 
The secondary outcomes included the criteria used for the 
prenatal ultrasound diagnosis of placenta previa and the 
criteria used to diagnose and grade PAS at birth.
results A total of 258 articles were reviewed and 13 
retrospective and 7 prospective studies were included in 
the analysis, which reported on 587 women with placenta 
previa and PAS. The meta- analysis indicated a significant 
(p<0.001) heterogeneity between study estimates for 
the prevalence of placenta previa, the prevalence of 
placenta previa with PAS and the incidence of PAS in 
the placenta previa cohort. The median prevalence of 
placenta previa was 0.56% (IQR 0.39–1.24) whereas the 
median prevalence of placenta previa with PAS was 0.07% 
(IQR 0.05–0.16). The incidence of PAS in women with a 
placenta previa was 11.10% (IQR 7.65–17.35).
Conclusions The high heterogeneity in qualitative and 
diagnostic data between studies emphasises the need 
to implement standardised protocols for the diagnoses 
of both placenta previa and PAS, including the type of 
placenta previa and grade of villous invasiveness.
PrOSPErO registration number CRD42017068589
IntrODuCtIOn
Placenta accreta is a pathological condition 
of placentation associated with a high risk 
of massive obstetric haemorrhage during 
delivery. Initially described in 1937 by Irving 
and Hertig1 as the abnormal adherence 
of the placenta to the myometrium due to 
the partial or complete absence of decidua 
basalis, it was subsequently redefined by Luke 
et al2 as a spectrum of abnormally adherent 
and invasive placentation disorders. Placenta 
accreta is now graded according to the depth 
of the villous penetration into the uterine 
wall starting with the abnormally adherent 
placenta or creta, where the villi attach 
directly to the surface of the myometrium 
without invading it, and extending to the 
invasive grades of placenta increta, where 
the villi penetrate deeply into the myome-
trium up to the uterine serosa, and placenta 
percreta, where the invasive villous tissue 
penetrates through the uterine serosa often 
entering the surrounding pelvic tissues.3–5 
The different grades of the placenta accreta 
spectrum (PAS) can coexist in the same spec-
imen and can be focal (just a small area of the 
placental bed) or extensive (including much 
of the placental bed).2
Over the last two decades, a growing body of 
epidemiology research has identified the effect 
of the rapid increase in caesarean delivery rates 
on the risks of PAS.6–10 The main additional 
risk factor after a previous caesarean delivery 
is placenta previa. A large multicentric US 
cohort study noted that for women presenting 
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with placenta previa and prior caesarean delivery, the risk 
of PAS was 3%, 11%, 40%, 61% and 67% for first, second, 
third, fourth and fifth or more caesarean deliveries, 
respectively.7 A national case–control study using the UK 
Obstetric Surveillance System found that the incidence 
of PAS increases from 1.7 per 10 000 births overall to 577 
per 10 000 births in women with both a previous caesarean 
delivery and placenta previa.8
Both abnormal adherence and invasion of villous tissue 
into the myometrium result in failure of the placenta to 
separate spontaneously from the uterine wall at delivery.2–4 
When unsuspected at the time of delivery, attempts to 
manually remove accreta villous tissue typically provoke 
rapid bleeding from the uteroplacental circulation.5 11 In 
invasive cases, this can lead to massive obstetric haemor-
rhage due to the disruption of the deep uterine vascula-
ture of the increta or percreta area.4 5 Not surprisingly, 
prenatal diagnosis of PAS has been shown to decrease 
maternal morbidity and mortality, and has thus become 
essential in improving its management.12 13 Tabsh et al 
were the first in 1982 to report on the prenatal ultrasound 
diagnosis of a case of placenta increta.14 A recent system-
atic review and meta- analysis of prenatal ultrasound diag-
nosis of placenta previa with PAS in women with a history 
of caesarean delivery has found that the overall diagnostic 
accuracy of ultrasound in specialist units is in 90.9%.15 
However, in countries with well- established screening 
programmes for fetal anomalies, over half the cases of 
PAS are not diagnosed before delivery.8 10
Accreta placentation and in particular its invasive forms 
are impacting maternal health outcomes globally and its 
prevalence is likely to increase. Women with a history of 
previous caesarean delivery presenting with placenta previa 
complicated by PAS in an ongoing pregnancy are now the 
cohort of obstetric patients with the highest risk of delivery 
complications,16 however, their epidemiology has not been 
comprehensively reviewed yet. Health provision for the 
development of maternity centres with specialist teams, 
equipment, drugs, blood bank and intensive care infra-
structure to safely manage women presenting with placenta 
previa and PAS requires an accurate evaluation of its epide-
miology. The objective of this meta- analysis is to review the 
epidemiology of women presenting with placenta previa 
and to examine the different criteria used by the authors of 
cohort studies to diagnose placenta previa and PAS prena-
tally and to confirm the diagnosis of PAS at birth.
MAtErIAlS AnD MEthODS
A systematic review was undertaken of articles providing data 
on prevalence and incidence of PAS in women presenting 
with a placenta previa where the populations sampled were 
defined. PubMed, Google Scholar,  ClinicalTrials. gov and 
MEDLINE were searched for studies published between 
the first prenatal ultrasound description of placenta accreta 
in August 1982 by Tabsh et al14 and September 2018. The 
overall search strategy was inclusive of MeSH headings for 
the following terms ‘placenta accreta, placenta increta, 
placenta percreta, abnormally invasive placenta, morbidly 
adherent placenta and major placenta previa’ (search 
strategy in online supplementary data 1). Title, abstracts 
and full text were independently assessed by the authors for 
content, data extraction and analysis. Additional relevant 
studies were identified from reference lists of reviews and 
editorials and by handsearching key journals and websites. 
All search results were combined in a reference database. 
Duplicates were removed by hand. The search was limited 
to articles published in English.
Two independent investigators (EJ and LG) selected 
studies in two stages. The abstracts of all potentially rele-
vant papers were individually examined for suitability. 
Papers were only ruled out at this stage if they obviously 
did not meet the inclusion criteria. The remainders were 
obtained in full text and were independently assessed 
for content, data extraction and analysis. Disagreements 
between the two original reviewers were resolved by 
discussion with the third investigator (JL- R). Articles were 
excluded if; they were published before August 1982, 
contained no data on the study population such as the 
overall pregnancies, births and/or deliveries numbers, 
were case reports or were overlapping.
Study characteristics were extracted using a prede-
signed data extraction protocol including: author institu-
tion, year of publication, country of origin, study period, 
study type (retrospective, single institution, multiple insti-
tutions), total number of cases in the study population, 
type of placenta previa, diagnosis of PAS at birth (search 
strategy in online supplementary data 2). Outcome 
measures included the need to perform a peripartum 
hysterectomy and direct maternal mortality. Prior surgical 
history was also recorded. The reference standard for 
differential diagnosis between minor and major placenta 
previa was recorded based on the placental position inside 
the uterine cavity on transvaginal ultrasound with relation 
to the internal cervical os. For the diagnosis of accreta 
placentation, we referred to the clinical grading based on 
surgical findings at delivery as previously described17 and 
to histopathological findings when a caesarean hyster-
ectomy was performed, that is, placental villi directly 
attached to the myometrium without interposing decidua 
or invading the uterine wall.
Two independent reviewers (EJ and LG) undertook the 
quality assessment with difference agreed by consensus. 
The Newcastle- Ottawa scale for observational studies 
was used to establish the risk of bias in selection (repre-
sentativeness of the exposed cohort, ascertainment of 
exposure and the demonstration that the outcome of 
interest was not present at the start of the study), compa-
rability (evaluation of the cohorts based on the design 
or analysis) and outcome assessment.18 These included 
retrospective versus prospective studies, single versus 
multiple institutions studies, prenatal ultrasound descrip-
tion of low- lying/placenta previa and PAS, histopatho-
logical confirmation of the diagnosis of the PAS and 
corresponding grade of invasiveness and detailed data 
on management and maternal outcomes. Studies that 
Protected by copyright.
 o
n
 June 12, 2020 at Kobenhavns Universitets Bibliotek.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031193 on 12 November 2019. Downloaded from 
3Jauniaux E, et al. BMJ Open 2019;9:e031193. doi:10.1136/bmjopen-2019-031193
Open access
Figure 1 Flow diagram showing the selection of reports 
included in the review.
scored four stars for selection, two stars for comparability 
and three stars for ascertainment of the outcome were 
regarded to have a low risk of bias. Studies with two or 
three stars for selection, one for comparability and two 
for outcome ascertainment were considered to have a 
medium risk of bias. We deemed any study with a score of 
one for selection or outcome ascertainment, or zero for 
any of the three domains, to have a high risk of bias. No 
study was excluded based on the risk of bias assessment.
Analyses were conducted using STATA software (V.15; 
StataCorp). Standard Kurtosis analysis indicated that some 
values were not normally distributed and study specific 
estimates are therefore presented as median and IQR. A 
random- effects model was used to combine the studies 
while incorporating variations among studies unless there 
were three or less studies contributing to the meta- analysis 
in which case a fixed- effect model was used. Statistical 
heterogeneity was assessed with the Cochran’s Q- test and 
the I2 statistic (the proportion of variation in study estimates 
because of heterogeneity rather than sampling error). 
Forest plots are presented to graphically summarise the 
study results and the pooled results. A test for heterogeneity 
between subgroups (ie, study types) was conducted.
Patients and public involvement
Patients and the public were not involved in the design or 
planning of the study.
rESultS
The initial search provided 256 records with cross- 
referencing providing an additional two studies, making a 
total of 258 potentially relevant articles. After exclusion of 
duplicates and the two which were not available (figure 1), 
220 remained. On screening the titles and abstracts, a 
further 162 were excluded as the reported outcomes were 
not relevant, leaving 58 studies which were obtained for full 
text review. An additional 38 articles were excluded after full 
review including letters (n=16), narrative reviews (n=10) 
commentaries (n=9), conference proceedings (n=2) and 
duplication of data in another publication (n=1), leaving 
20 articles for the final analysis.19–38
There were 13 retrospective19 20 23 25–27 29–31 33–35 38 and 
7 prospective21 22 24 28 32 36 37 studies including a total 
of 1 207 296 births and 23 864 cases referred as preg-
nancies. There were 15 studies from a single institu-
tion19–24 27–30 32–34 37 38 and 5 from multiple institutions25 31 
or a geographical region.26 35 36 Overall, 18 studies had 
low or medium risk of bias (full data in online supple-
mentary data 3).
Table 1 presents the epidemiology data of the 20 
studies. These studies included 587 women with placenta 
previa complicated by PAS out of 6628 cases of placenta 
previa. The median prevalence of placenta previa in the 
20 studies was 0.56% (IQR 0.39–1.24) whereas the median 
prevalence of placenta previa with PAS was 0.07% (IQR 
0.05–0.16). The median incidence of PAS in women with 
a placenta previa was 11.10% (IQR 7.65–17.35).
All authors except two29 33 reported on the criteria used 
for the prenatal ultrasound diagnosis of placenta previa. 
Six studies24 26 30 32 37 38 only included major placenta previa 
in their cohort as defined as the placenta completely 
covering or partially covering the internal os of the cervix. 
The others included both major and minor placenta 
previa. The definition of minor placenta previa varied 
with two studies31 36 using the placental edge being <2 cm 
from the internal os, two studies using <3 cm22 2323 and one 
study using <3 cm or <5 cm if associated with abnormal 
fetal presentation.21 The gestational age at confirmation 
of the prenatal diagnosis of placenta previa was reported 
in six studies22–24 28 32 37 and ranged between 20 and 34 
weeks and in one study the diagnosis of placenta previa 
was confirmed at birth when the placenta was found to be 
inserted in the lower segment.19
The ultrasound diagnostic signs for PAS were reported in 
six studies24 28 30 32 36 37 with two studies also reporting on the 
use of MRI.29 38 The clinical criteria used for the diagnosis of 
PAS at birth were reported by nine studies19 20 23 27 28 30 33 36 37 
and included a difficult delivery of the placenta without easy 
separation uterine wall or requiring a ‘piecemeal removal’ 
associated with heavy bleeding and excessive bleeding 
from the placental bed after placental delivery. One author 
described the presence of invasive villous tissue at delivery27 
and one the need to suture the placental bed.23 None of 
the other authors reported on the gross appearance of the 
uterus or surgical findings at the time of caesarean delivery. 
In 12 studies,19 23 24 27–31 33 34 36 37 the prenatal and/or clinical 
diagnosis was confirmed by histopathological examination 
with detailed description of the microscopic criterion only 
reported in six.19 27 28 30 31 37 Detailed histopathological find-
ings on the depth of villous invasiveness were reported in 
9 studies24 27–29 31 33 34 36 37 out of the 20 studies (table 2). 
These included 283 cases of placenta previa accreta graded 
for 171 (60.4%) as placenta accreta (adherent), 74 (26.2%) 
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Table 1 Prevalence of placenta previa with placenta accreta spectrum (PAS) per pregnancies or births in the corresponding 
obstetric population and incidence of PAS per cohorts of placenta previa
References Obstetric population Prevalence (%) Incidence (%)
Chattopadhyay et al19 41 206 births 26 (0.063) 26/222 (11.7)
Zaki et al20 23 070 births 12 (0.052) 12/110 (10.9)
Ziadeh et al21 18 651 births 13 (0.070) 13/65 (20.0)
Ghourab22 18 670 births 11 (0.059) 11/138 (8.0)
Bahar et al23 42 487 births 53 (0.125) 53/306 (17.3)
Hamada et al24 2413 births 5 (0.207) 5/70 (7.1)
Jang et al25 35 030 births 53 (0.151) 53/560 (9.5)
Rosenberg et al26 185 476 births 23 (0.012) 23/779 (3.0)
Kassem and Alzahrani27 29 053 births 25 (0.085) 25/122 (20.5)
Maher et al28 24 661 births 42 (0.170) 42/577 (7.3)
Alchalabi et al29 16 845 births 23 (0.137) 23/81 (28.4)
Asicioglu et al30 112 819 births 46 (0.041) 46/364 (12.6)
Sumigama et al31 96 670 births 46 (0.048) 46/954 (4.8)
Ahmed et al32 3841 births 14 (0.365) 14/52 26.9
Cheng and Lee33 81 497 births 39 (0.048) 39/921 (4.2)
Cho et al34 11 210 pregnancies 39 (0.348) 39/442 (8.8)
Kollmann et al35 218 876 births 13 (0.006) 13/328 (4.0)
Pilloni et al36 108 000 births 37 (0.034) 37/314 (11.8)
Rezk and Shawky37 12 654 pregnancies 53 (0.419) 53/74 (71.6)
Wortman et al38 148 031 births 14 (0.010) 14/157 (8.9)
Table 2 Studies presenting detailed histopathological data on the depth of villous invasiveness (PAS grades)
References
No of cases analysed/no of
cases included in the study
PAS grades
PC (%) PI (%) PP (%)
Hamada et al24 5/5 3 (60.0) 2 (40.0) --
Kassem and Alzahrani27 19/25 13 (68.4) 5 (26.3) 1 (5.3)
Maher et al28 42/42 28 (66.6) 13 (31.0) 1 (2.4)
Achalabi et al29 23/23 15 (65.2) 4 (17.4) 4 (17.4)
Sumigama et al31 46/46 14 (30.4) 21 (45.7) 11 (23.9)
Cheng and Lee33 39/39 36 (92.3) -- 3 (7.7)
Cho et al34 39/39 24 (37.4) 11 (31.3) 4 (31.3)
Pilloni et al36 17/37 7 (41.2) 4 (23.5) 6 (35.3)
Rezk and Shawky37 53/53 31 (58.5) 14 (26.4) 8 (15.1)
Total 283/309 171 (60.4) 74 (26.2) 38 (13.4)
PAS, placenta accreta spectrum
as placenta increta and 38 (13.4%) as placenta percreta. 
These studies included a total of 383 003 pregnancies 
or births and the prevalence for the different grades of 
placenta previa accreta was 0.05%, 0.02% and 0.01% for 
creta, increta and percreta, respectively.
The meta- analysis indicated statistically significant 
(p<0.001) level of overall heterogeneity between study 
estimates for the prevalence of placenta previa (figure 2), 
the prevalence of placenta previa with PAS (figure 3) 
and the incidence of PAS in the placenta previa cohort 
(figure 4). There was strong evidence of inconsistency 
between study types with I2 values greater 85%. The differ-
ence in heterogeneity between prospective versus retro-
spective studies was not statistically significantly (p=0.839) 
different (figure 2) whereas it was significant (p=0.014) 
for the prevalence of placenta previa accreta (figure 3). 
Adjusting for type of study (prospective vs retrospec-
tive) did not reduce inconsistency between studies. The 
in- between placenta previa major only versus minor and 
major placental previa was not significant (p=0.067) for 
Protected by copyright.
 o
n
 June 12, 2020 at Kobenhavns Universitets Bibliotek.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031193 on 12 November 2019. Downloaded from 
5Jauniaux E, et al. BMJ Open 2019;9:e031193. doi:10.1136/bmjopen-2019-031193
Open access
Figure 2 Forest plots showing the heterogeneity of prevalence data in prospective and retrospective cohort studies of women 
presenting with a placenta previa. Only first author’s name is given for each reference. ES, effect size.
Figure 3 Forest plots showing heterogeneity in the prevalence data for prospective and retrospective cohort studies of women 
diagnosed with placenta previa accreta. Only first author’s name is given for each reference. ES, effect size.
the incidence of PAS in patient with placenta previa 
(figure 4).
All authors but two22 23 reported on prior surgical 
history including caesarean section,19–21 24–38 uterine 
curettage28 30–32 34 37 38 and myomectomy.28 36 37 Data on 
surgical management were available in 14 out of the 
20 studies19 20 23 27–31 33–38 with 314 out of 441 women 
presenting with a placenta previa complicated by PAS. 
The median peripartum hysterectomy rate of 69.2% (IQR 
50.0–84.0). Data on maternal mortality were available in 
13 studies19–21 23 25 27–30 32 35 37 38 and PAS accounted for 
5 maternal deaths19 20 25 29 30 out of 387 (1.3%) cases of 
placenta previa with PAS.
DISCuSSIOn
This study provides a comprehensive evaluation of 
the prevalence of placenta previa complicated by PAS 
and the incidence of PAS in women presenting with a 
placenta previa. Women with a prior history of caesarean 
delivery presenting with a low- lying/placenta previa 
represent more than 90% of the cases of PAS.8 10 16 The 
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Figure 4 Forest plots showing the heterogeneity in cohort studies reporting incidence data for women diagnosed with 
placenta previa major and PAS and those with either placenta previa minor or major and PAS. ES, effect size.; PAS, placenta 
accreta spectrum.
meta- analysis indicates high heterogeneity for both the 
prenatal diagnosis of placenta previa and for the confir-
mation of the diagnosis of PAS at delivery. These find-
ings highlight the need to use international standardised 
clinical protocols for the screening and management of 
this complex obstetric condition. The current situation 
limits the capacity building of healthcare providers on 
improvements in training, implementation of guidelines 
and changes in clinical practice behaviour.
Defining the position of the placenta inside the uterus 
was one of the first aims of obstetric ultrasound exam-
ination.39 40 Following the development of real- time ultra-
sound imaging, placental location became an integral 
part of the mid- pregnancy ultrasound examination.41 
Placenta previa was initially described with transabdom-
inal scan as a placenta developing within the lower uterine 
segment and classified according to the relationship and/
or the distance between the lower placental edge and the 
internal os of the uterine cervix, that is, minor placenta 
previa when lower edge is inside the lower uterine segment 
down to the internal os and major placenta previa when 
the placenta covers the cervix. Minor placenta previa can 
be further subdivided into low- lying placenta when the 
lower edge does not reach the internal os and marginal 
placenta previa when it does. Major placenta previa can 
also be described as partial or complete depending on the 
amount of placental tissue covering the cervix. The use 
of transvaginal scanning has allowed for a more precise 
evaluation of the distance between the placental edge 
and the internal os42 43 but as demonstrated in our meta- 
analysis, the reporting of the ultrasound criteria used for 
the diagnosis of placenta previa has been heterogeneous. 
In addition, we found also wide variation in the gesta-
tional age at diagnosis. The timing of the confirmation 
of the diagnosis has a direct impact on epidemiology data 
as up to 70% of minor placenta previa at 20–23 weeks 
of gestation will resolve by 32–35 weeks.44 45 An expert 
panel of the American Institute of Ultrasound in Medi-
cine46 has recently recommended ceasing the use of 
the terms ‘partial’ and ‘marginal’ and using the term 
‘placenta previa’ only when the placenta lies directly 
over the internal os. The placenta should be reported as 
‘low- lying’ when the placental edge is less than 2 cm from 
the internal os and as normal when the placental edge 
is more than 2 cm from the internal os. The findings of 
our meta- analysis highlight the need for the use of such a 
classification in further studies.
Only 6 of the 20 studies included in the present meta- 
analysis provided data on the prenatal ultrasound diag-
nosis of PAS in patients with placenta previa. We included 
in the systematic review all studies published since the 
first ultrasound description of PAS by Tabsh et al.14 We 
found no studies between 1982 and 1993 (table 1), which 
corresponds to the time when high- resolution grey- scale 
ultrasound imaging became widely available. Colour 
Doppler imaging was introduced for the diagnosis of PAS 
in 1992,47 however, the sensitivity and specificity of grey- 
scale imaging alone in diagnosing for placenta previa 
accreta are high when performed by the experience oper-
ators.15 These findings indicate that the prenatal diag-
nosis of PAS can be performed using standard ultrasound 
equipment. Unlike placenta previa which is routinely 
screened for at the time of the fetal anomaly scan, PAS 
is currently not screened for and the data available on 
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the prenatal diagnosis of the condition come exclusively 
from specialist centres.16 In these centres, the diagnostic 
accuracy of ultrasound imaging is over 90%, but similar 
to placenta previa, the description of the ultrasound signs 
used for the diagnosis of PAS has also been highly vari-
able over the last two decades.47 48 The European Working 
Group on Abnormally Invasive Placenta and the Abnor-
mally Invasive Placenta international expert group have 
recently proposed standardised descriptions of the ultra-
sound signs used for the prenatal diagnosis and a protocol 
for the ultrasound assessment of PAS.49 50 The use of these 
protocols in prospective studies should also facilitate the 
screening of patients at high risk of PAS and in particular 
those with multiple prior caesarean deliveries presenting 
with a low- lying or placenta previa.51
We found significant heterogeneity in the qualitative 
definition and diagnosis of PAS at birth among the nine 
studies that provided a description of the clinical find-
ings.19 20 23 27 28 30 33 36 37 Only one of these studies described 
the invasive appearance of placental tissue at delivery27 
whereas the others reported a difficult delivery of the 
placenta without easy separation from the uterine wall 
or requiring a ‘piecemeal removal’ associated with heavy 
bleeding as diagnostic of PAS. These clinical criteria 
were first described by Irving and Hertig1 in 1937 who 
did not have invasive cases in their cohort limiting their 
definition to abnormally adherent placenta and not to 
placenta increta or percreta. This definition also fails to 
clearly differentiate between abnormal adherence and 
placental retention as both present with similar clinical 
symptoms and aetiology52 leading to possible over diag-
nosis of placenta previa accreta. Similarly, the finding of 
excessive bleeding from the placental bed after delivery 
of the placenta is a common complication of non- 
accreta placenta previa due to the implantation of the 
placenta in the lower uterine segment which contains 
less muscular fibres than the upper segment and is 
often thinner and dehiscent after multiple caesarean 
deliveries.
Detailed histopathological reports can only be obtained 
in those patients who have a hysterectomy or a partial 
myometrial resection and thus in many studies there is 
not histopathological confirmation of the clinical diag-
nosis. The main histological diagnostic criteria of accreta 
placentation, that is, absence of decidua between the 
tip of anchoring villi and the superficial myometrium, is 
found with increasing incidence with advancing gestation 
in pregnancies with no clinical evidence of PAS.5 Thus, 
the combination of clinical criteria that do not differen-
tiate between placenta retention and adherent accreta 
and the use of non- diagnostic criteria of villous invasive-
ness may result in the overdiagnosis of the adherent grade 
of PAS (table 2), in particular in those studies reporting 
a low rate of caesarean hysterectomy.28 36 Overall, this 
can explain the wide range in the prevalence (0.04%–
0.42%) of placenta previa with PAS and incidence (2.9%–
71.6%) of PAS in women presenting with placenta previa 
(figures 3 and 4).
Overall, management strategies and outcomes will vary 
depending on the accuracy of prenatal diagnosis, local 
surgical expertise and more recently access to a centre of 
excellence with multidisciplinary team approach.53 54 In 
cases of high suspicion of PAS during caesarean delivery, 
60%–70% of obstetricians- gynaecologists proceed with a 
peripartum hysterectomy.55 56 By contrast with a conser-
vative management approach, radical surgery is often 
considered to be safer, in particular in cases of invasive 
placentation.57 The association between a placenta previa 
and a PAS increases the risks of both maternal morbidity 
and mortality. In the present study, we found that a 
caesarean hysterectomy was the primary management 
option in around 70% of the patients presenting with a 
placenta previa and PAS. The interstudy range was wide 
with four studies19 21 29 37 reporting peripartum hysterec-
tomy rates <50%, five28 31 32 34 36 had rates between 50% 
and 99% and four22 30 35 38 had rates of 100%. This may be 
due to difference in study protocols, local expertise and 
the impact of prenatal diagnosis on management strate-
gies but also as suggested by our analysis to difference in 
the rates of the different grades of PAS and the accuracy 
of clinical diagnosis at birth and detailed histopatholog-
ical examination confirming the diagnosis.
The main limitations of this review are the quality of 
the published data. Thirteen out of 20 studies included in 
the analysis studies were retrospective and there was wide 
variation in the use of different ultrasound criteria for 
the prenatal diagnosis of placenta previa, in the clinical 
diagnosis of PAS at delivery and in the authors providing 
detailed histopathology data to confirm the clinical diag-
nosis. This is hampering the meta- analysis of the clinical 
outcomes in particular the incidence of major haemor-
rhage at delivery and the need and amount of blood trans-
fusion but also the choice in management protocols and 
in particular the use of conservative management proce-
dures. We would not, therefore, recommend the use of 
the pooled estimates beyond that of a support towards the 
development of standardised diagnostic protocols.
The prevalence of PAS in the general population of 
women giving birth varies widely.8 10 58 59 A systematic 
review and meta- analysis of the prevalence of placenta 
praevia has found evidence suggestive of regional varia-
tion.60 As both conditions are often associated with prior 
caesarean sections, it is likely that national and local 
caesarean delivery rates, expertise in diagnosing both 
conditions antenatally and access to perinatal pathol-
ogist to confirm the diagnosis of PAS at birth will influ-
ence these epidemiology data. There is a need for further 
prospective multicentre studies with participatory meth-
odologies involving local service providers and facility 
management to accurately evaluate the consequences of 
high caesarean sections rates on maternal health within 
a particular population. Within this context, accurate 
epidemiological data on PAS disorders are essential in 
planning screening programmes and in making provi-
sion for the development of centres of excellence for 
the management of this increasingly common complex 
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obstetric condition. While the concept of core outcome 
measures within clinical trials is now well recognised and 
championed, greater efforts are required to disseminate 
this approach in epidemiological research to facilitate 
global estimation and recognition of problems emerging 
on a worldwide scale. Our study supports implementa-
tion, in both clinical practice and in reporting data on 
placenta previa accreta in the medical literature, of stan-
dardised protocols for prenatal diagnosis of both placenta 
previa and PAS, for the clinical diagnosis of PAS at birth 
and for the histopathological confirmation examination.
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